Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Leid RW and Potter KA | Inflammation and mediators of lung injury. | 1985 | Vet. Clin. North Am. Food Anim. Pract. | pmid:3907779 |
Shukla SD | Platelet activating factor-stimulated formation of inositol triphosphate in platelets and its regulation by various agents including Ca2+, indomethacin, CV-3988, and forskolin. | 1985 | Arch. Biochem. Biophys. | pmid:3875314 |
Roubin R and Benveniste J | Formation of prostaglandins, leukotrienes and paf-acether by macrophages. | 1985 | Comp. Immunol. Microbiol. Infect. Dis. | pmid:3910339 |
Malone B et al. | Inactivation of platelet activating factor by rabbit platelets. Lyso-platelet activating factor as a key intermediate with phosphatidylcholine as the source of arachidonic acid in its conversion to a tetraenoic acylated product. | 1985 | J. Biol. Chem. | pmid:3918041 |
MacIntyre DE et al. | Endogenous and pharmacological mechanisms for the regulation of human platelet cytosolic free Ca2+. | 1985 | Nouv Rev Fr Hematol | pmid:2997706 |
Lachachi H et al. | Inhibition of transmembrane movement and metabolism of platelet activating factor (PAF-acether) by a specific antagonist, BN 52021. | 1985 | Biochem. Biophys. Res. Commun. | pmid:2998370 |
Hwang SB et al. | trans-2,5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor. | 1985 | J. Biol. Chem. | pmid:2999126 |
Brain SD and Williams TJ | Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. | 1985 | Br. J. Pharmacol. | pmid:2416378 |
O'Neill C | Partial characterization of the embryo-derived platelet-activating factor in mice. | 1985 | J. Reprod. Fertil. | pmid:4067921 |
Mallet AI and Cunningham FM | Structural identification of platelet activating factor in psoriatic scale. | 1985 | Biochem. Biophys. Res. Commun. | pmid:3970690 |
Valone FH | Inhibition of binding of the platelet-activating factor AGEPC to platelets by the AGEPC analog rac-3-(N-n-octadecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate (CV-3988). | 1985 | Biochem. Biophys. Res. Commun. | pmid:3970703 |
Camussi G and Brentjens JR | Inhalation of horseradish peroxidase by rabbits with specific IgE antibodies results in release into the circulation of platelet-activating factor and in lung lesions. | 1985 | Clin. Immunol. Immunopathol. | pmid:3971603 |
Chesney CM et al. | Desensitization of human platelets by platelet activating factor. | 1985 | Biochem. Biophys. Res. Commun. | pmid:3977920 |
Nakayama R et al. | Generation of acetyl glyceryl ether phosphorylcholine from the rat skin and muscle tissues stimulated by moxibustion. | 1985 | Biochem. Biophys. Res. Commun. | pmid:3977939 |
Ardaillou N et al. | Vasoconstrictor-evoked prostaglandin synthesis in cultured human mesangial cells. | 1985 | Am. J. Physiol. | pmid:3918460 |
Pritchard PH et al. | The degradation of platelet-activating factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier disease). | 1985 | Blood | pmid:4063532 |
Wimberly HC et al. | Functional and biochemical characterization of immunologically derived equine platelet-activating factor. | 1985 | Vet. Pathol. | pmid:4035942 |
Ludwig JC et al. | Modulation of platelet-activating factor (PAF) synthesis and release from human polymorphonuclear leukocytes (PMN): role of extracellular albumin. | 1985 | Arch. Biochem. Biophys. | pmid:4037794 |
Surles JR et al. | Facile synthesis of platelet-activating factor and racemic analogues containing unsaturation in the sn-1-alkyl chain. | 1985 | J. Med. Chem. | pmid:4038418 |
Aul C et al. | [Thrombotic thrombocytopenic purpura]. | 1985 | Klin. Wochenschr. | pmid:4038757 |
Atkins JN | Platelet-aggregating factor in thrombotic thrombocytopenic purpura. | 1985 | Ann. Intern. Med. | pmid:4038861 |
Sugiura T et al. | Transacylation of 1-O-alkyl-SN-glycero-3-phosphocholine (lyso platelet-activating factor) and 1-O-alkenyl-SN-glycero-3-phosphoethanolamine with docosahexaenoic acid (22:6 omega 3). | 1985 | Biochem. Biophys. Res. Commun. | pmid:2935146 |
Oda M et al. | Molecular species of platelet-activating factor generated by human neutrophils challenged with ionophore A23187. | 1985 | J. Immunol. | pmid:3917470 |
Kilpatrick JM and Virella G | Inhibition of platelet-activating factor by rabbit C-reactive protein. | 1985 | Clin. Immunol. Immunopathol. | pmid:4042435 |
Monnens L et al. | Platelet aggregating factor in the epidemic form of hemolytic-uremic syndrome in childhood. | 1985 | Clin. Nephrol. | pmid:4042442 |
Pirotzky E et al. | Vascular permeability induced by Paf-acether (platelet-activating factor) in the isolated perfused rat kidney. | 1985 | Agents Actions | pmid:4003192 |
Page CP et al. | Platelet activating factor (Paf-acether) may account for late-onset reactions to allergen inhalation. | 1985 | Agents Actions | pmid:4003195 |
Page CP et al. | Suppression of Paf-acether responses: an anti-inflammatory effect of anti-asthma drugs. | 1985 | Agents Actions | pmid:4003196 |
O'Flaherty JT | Neutrophil degranulation: evidence pertaining to its mediation by the combined effects of leukotriene B4, platelet-activating factor, and 5-HETE. | 1985 | J. Cell. Physiol. | pmid:2981891 |
Khan SN et al. | Desaggregation of PAF-acether-aggregated platelets by verapamil and TMB-8 with reversal of phosphorylation of 40K and 20K proteins. | 1985 | Eur. J. Pharmacol. | pmid:3920056 |
Bushfield M et al. | Inhibition of platelet-activating-factor-induced human platelet activation by prostaglandin D2. Differential sensitivity of platelet transduction processes and functional responses to inhibition by cyclic AMP. | 1985 | Biochem. J. | pmid:3002327 |
Grandel KE et al. | Association of platelet-activating factor with primary acquired cold urticaria. | 1985 | N. Engl. J. Med. | pmid:2410790 |
Bussolino F et al. | Alkyl-ether phosphoglycerides influence calcium fluxes into human endothelial cells. | 1985 | J. Immunol. | pmid:2411812 |
Johnson HM and Torres BA | Mechanism of calcium ionophore A23187-induced priming of bone marrow-derived macrophages for tumor cell killing: relationship to priming by interferon. | 1985 | Proc. Natl. Acad. Sci. U.S.A. | pmid:2412225 |
Fjellner B and Hägermark O | Experimental pruritus evoked by platelet activating factor (PAF-acether) in human skin. | 1985 | Acta Derm. Venereol. | pmid:2416164 |
Shen TY et al. | Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects. | 1985 | Proc. Natl. Acad. Sci. U.S.A. | pmid:2983307 |
Avdonin PV et al. | [Mechanism of increase in Ca2+ level in platelet cytoplasm induced by aggregating factors]. | 1985 | Biokhimiia | pmid:3000463 |
Cox CP et al. | VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF). | 1984 Mar-Apr | Peptides | pmid:6206481 |
Vemulapalli S et al. | Cardiovascular and renal action of platelet-activating factor in anesthetized dogs. | 1984 Jul-Aug | Hypertension | pmid:6378787 |
Wodzinowska B and Krajewski T | [Role of blood platelets and their membrane in the process of hemostasis]. | 1984 Jan-Feb | Postepy Hig Med Dosw | pmid:6093087 |
Gordeev KIu et al. | [A bioregulator of lipid nature--a platelet activating factor (PAF)]. | 1984 | Bioorg. Khim. | pmid:6099122 |
Wang ZY | [Advances in the physiopathology of platelets]. | 1984 | Zhonghua Nei Ke Za Zhi | pmid:6099795 |
Feuerstein G et al. | Hypotension produced by platelet-activating factor is reversed by thyrotropin-releasing hormone. | 1984 | Circ. Shock | pmid:6432359 |
Parnham MJ et al. | Regulation of the oxidative burst of macrophages by lipid mediators. | 1984 | Agents Actions Suppl. | pmid:6433680 |
Basran GS et al. | Platelet-activating factor: a possible mediator of the dual response to allergen? | 1984 | Clin. Allergy | pmid:6697475 |
Kelton JG et al. | Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia. | 1984 | J. Lab. Clin. Med. | pmid:6699475 |
El Tamer A et al. | Studies on ether phospholipids. I. A new method of determination using phospholipase A1 from guinea pig pancreas: application to Krebs II ascites cells. | 1984 | Biochim. Biophys. Acta | pmid:6712966 |
Touqui L et al. | Dissociation between inhibition of phospholipid methylation and production of PAF-acether by rabbit platelets. | 1984 | Experientia | pmid:6714369 |
Iñarrea P et al. | Characteristics of the binding of platelet-activating factor to platelets of different animal species. | 1984 | Eur. J. Pharmacol. | pmid:6510472 |
Kornecki E et al. | Platelet-activating factor-induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines. | 1984 | Science | pmid:6150550 |